Outcomes for olfactory neuroblastoma treated with induction chemotherapy

Shirley Y. Su; Diana Bell; Renata Ferrarotto; Jack Phan; Dianna Roberts; Michael E. Kupferman; Steven J. Frank; C. David Fuller; G. Brandon Gunn; Merrill S. Kies; Bonnie S. Glisson; Ehab Y. Hanna

doi:10.1002/hed.24822

Outcomes for olfactory neuroblastoma treated with induction chemotherapy

Shirley Y. Su, Diana Bell, Renata Ferrarotto, Jack Phan, Dianna Roberts, Michael E. Kupferman, Steven J. Frank, C. David Fuller, G. Brandon Gunn, Merrill S. Kies, Bonnie S. Glisson, Ehab Y. Hanna

Research output: Contribution to journal › Article › peer-review

57 Scopus citations

Abstract

Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.

Original language	English (US)
Pages (from-to)	1671-1679
Number of pages	9
Journal	Head and Neck
Volume	39
Issue number	8
DOIs	https://doi.org/10.1002/hed.24822
State	Published - Aug 2017

Keywords

chemotherapy
induction chemotherapy
olfactory neuroblastoma
orbital preservation
skull base

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.24822

Cite this

@article{d73a8f7e916047b18329896257161fba,

title = "Outcomes for olfactory neuroblastoma treated with induction chemotherapy",

abstract = "Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.",

keywords = "chemotherapy, induction chemotherapy, olfactory neuroblastoma, orbital preservation, skull base",

author = "Su, {Shirley Y.} and Diana Bell and Renata Ferrarotto and Jack Phan and Dianna Roberts and Kupferman, {Michael E.} and Frank, {Steven J.} and Fuller, {C. David} and Gunn, {G. Brandon} and Kies, {Merrill S.} and Glisson, {Bonnie S.} and Hanna, {Ehab Y.}",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = aug,

doi = "10.1002/hed.24822",

language = "English (US)",

volume = "39",

pages = "1671--1679",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "8",

}

TY - JOUR

T1 - Outcomes for olfactory neuroblastoma treated with induction chemotherapy

AU - Su, Shirley Y.

AU - Bell, Diana

AU - Ferrarotto, Renata

AU - Phan, Jack

AU - Roberts, Dianna

AU - Kupferman, Michael E.

AU - Frank, Steven J.

AU - Fuller, C. David

AU - Gunn, G. Brandon

AU - Kies, Merrill S.

AU - Glisson, Bonnie S.

AU - Hanna, Ehab Y.

PY - 2017/8

Y1 - 2017/8

N2 - Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.

AB - Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear. Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy. Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR. Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.

KW - chemotherapy

KW - induction chemotherapy

KW - olfactory neuroblastoma

KW - orbital preservation

KW - skull base

UR - http://www.scopus.com/inward/record.url?scp=85019972846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019972846&partnerID=8YFLogxK

U2 - 10.1002/hed.24822

DO - 10.1002/hed.24822

M3 - Article

C2 - 28561956

AN - SCOPUS:85019972846

SN - 1043-3074

VL - 39

SP - 1671

EP - 1679

JO - Head and Neck

JF - Head and Neck

IS - 8

ER -

Outcomes for olfactory neuroblastoma treated with induction chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this